Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEM-iSMART Sub-protocol C: Ruxolitinib + Venetoclax in Pediatric Relapsed/Refractory Hematologic Malignancies
2022-501867-42-01Phase 2Authorised
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib and venetoclax in acute lymphoblastic leukemia (ALL), Precursor B-cell lymphoblastic lymphoma (B-LBL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Maximum tolerated dose (MTD) and Best overall response rate (ORR). Planned start Oct 2024; status: authorised.
02
Drugs
ruxolitinibvenetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)Precursor B-cell lymphoblastic lymphoma (B-LBL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on 2022-501867-42-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501867-42-01.